A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Benralizumab (Primary)
- Indications Chronic urticaria
- Focus Therapeutic Use
- Acronyms ARROYO
- Sponsors AstraZeneca; AstraZeneca AB
Most Recent Events
- 30 Apr 2023 This trial has been Discontinued in Bulgaria, according to European Clinical Trials Database record.
- 19 Apr 2023 This trial has been Discontinued in Germany according to European Clinical Trials Database record.
- 18 Apr 2023 Status changed from active, no longer recruiting to completed.